Positive news for Zai Lab's Efgartigimod as rival drug is withdrawn and it is included in 2024 NDRL, leading to an 8.8% increase in top line but no change in operating loss. TP raised to $20.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.